Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALLAS adjuvant palbociclib study in HR-positive/HER2-negative early breast cancer
NL-OMON60642Phase 3Active, not recruiting
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of palbociclib in breast cancer (2 arms), sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoint: Invasive disease-free survival. Started May 2017; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60642.